

Bakers Union and FELRA Health and Welfare Fund

Quarterly Review
January – March 2023

June 29, 2023



Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Outcomes
 - Clinical Outcomes
 - Vigilant Outcomes
 - VCS Outcomes
7. Drug Pipeline

Your OptumRx Team

Paul Marcus

VP, Client Management
Labor & Trust

Holly Agoney

Strategic Account Executive
Labor & Trust

Caroline Atwood

Director, Client
Management
Labor & Trust

Autumn Leblanc

Pharmacy Account
Manager
Labor & Trust

Fabian Gonzales

Pharmacy Service
Specialist
Labor & Trust

Current Plan Design

☐ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,850 Individual / \$5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,850 Individual / \$3,700 Family

Co-pays			
Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
	Retail		Mail
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay		*Specialty: N/A

Plan 3 (group BFWRX3):		
Retail / Mail		
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

☐ Effective 7/1/19

- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

☐ Effective 8/1/2020

- ☐ Orphan Drug Program

☐ Effective 3/1/2021

- ☐ Opioid Mgmt – tighter refill window & UMs

☐ Effective 7/1/2021

- ☐ Premium Formulary
- ☐ Mandatory Mail (MSS)

☐ Effective 1/1/2022

- ☐ Split-fill/Smart-fill

☐ Effective 3/1/2022

- ☐ CCAA/VCS

☐ Effective 5/15/23

- ☐ Price Edge

Key Discussion Topics

- ❑ Per Member Per Month (PMPM) trend = 38.6% Specialty trend = 172.6%
- ❑ Specialty represents 1.4% of claims

- ❑ Top 5 disease states accounted for 77% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions


- ❑ Rebates – January – March 2023
 - ❑ Estimated - \$44,500

- ❑ Clinical Outcomes savings
 - ❑ **UM (PA, ST, QL)** – April 2022 – March 2023
 - ❑ Savings = \$93,100
 - ❑ **Vigilant** – April 2022 – March 2023
 - ❑ Savings = \$5,726
 - ❑ **VCS** – January – March 2023
 - ❑ Savings = \$8,664

Key Statistics

Key Statistics – Performance Summary

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -36.
- Number of utilizers has decreased by -31.

Total Rx's

CURRENT
1,735

PREVIOUS
2,055

PERCENT CHANGE
-15.6%

Total plan paid

CURRENT
\$280,188

PREVIOUS
\$214,373

PERCENT CHANGE
30.7%

Utilizers

CURRENT
305

PREVIOUS
336

PERCENT CHANGE
-9.2%

Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL


Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 38.6%, compared to the benchmark trend of 12.1%
- Member Paid Share changed by -1.6% period over period, compared to the benchmark of -8.1%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	43.8	42.7	2.5%	36.8	0.4%	36.8	0.3%
Plan paid PMPM	\$157.32	\$113.49	38.6%	\$119.55	12.1%	\$120.74	15.2%
Plan paid per Rx	\$161.49	\$104.32	54.8%	\$168.22	12.3%	\$153.06	15.2%
Rxs PMPM	0.974	1.088	-10.5%	0.711	-0.1%	0.789	0.0%
Average days supply	30.9	28.7	7.7%	39.9	0.5%	39.7	2.3%
Days supply PMPM	30.1	31.3	-3.6%	28.4	0.4%	31.3	2.3%
Member paid share	9.2%	9.4%	-1.6%	8.8%	-8.1%	15.1%	-6.5%
Member paid per Rx	\$16.38	\$10.77	52.1%	\$16.14	2.3%	\$27.27	6.4%
Generic dispensing rate	85.4%	82.1%	4.0%	87.4%	3.2%	87.3%	2.1%
GDR-without Vaccines	86.5%	86.7%	-0.3%	88.1%	-0.2%	88.2%	-0.7%
Home delivery rate	6.1%	4.1%	48.1%	7.6%	-1.8%	4.9%	0.5%
Retail 90 rate	1.8%	1.3%	45.8%	17.2%	0.1%	20.0%	4.7%
Percent of specialty plan paid	42.3%	21.5%	96.6%	46.4%	2.1%	51.4%	0.1%

Specialty Key Statistics

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -36.
- Number of utilizers has increased by 2.

Total Rxs

CURRENT

24

PREVIOUS

18

PERCENT CHANGE

33.3%

Total plan paid

CURRENT

\$118,659

PREVIOUS

\$46,171

PERCENT CHANGE

157.0%

Utilizers

CURRENT

7

PREVIOUS

5

PERCENT CHANGE

40.0%

Specialty Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 172.6%, compared to the benchmark trend of 14.5%
- Member Paid Share changed by 387.2% period over period, compared to the benchmark of -15.5%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Plan Paid PMPM	\$66.62	\$24.44	172.6%	\$55.48	14.5%	\$62.02	15.4%
Plan paid per Rx	\$4,944.13	\$2,585.07	92.7%	\$6,309.28	6.9%	\$6,010.27	7.7%
Rxs PMPM	0.013	0.010	41.4%	0.009	7.1%	0.010	7.1%
Average days supply	43.7	29.0	50.6%	33.5	1.7%	32.2	1.3%
Days supply PMPM	0.6	0.3	112.9%	0.3	9.0%	0.3	8.5%
Member paid share	7.0%	1.4%	387.2%	5.4%	-15.5%	9.7%	-11.4%
Member paid per Rx	\$370.38	\$37.22	895.0%	\$361.08	-10.6%	\$644.41	-5.9%
Generic dispensing rate	25.0%	50.0%	-50.0%	22.2%	-2.4%	21.6%	-3.3%
Home delivery rate	4.2%	5.6%	-25.0%	8.4%	-8.5%	6.2%	-6.2%
Retail 90 rate	25.0%	0.0%	0.0%	6.2%	8.9%	5.5%	7.2%

Trend Summary

Trend Summary

Trend

Plan paid PMPM has increased 38.6% over the previous period driven primarily by utilization in traditional and utilization for specialty.

Specialty represents 1.4% of claims.



+26.5% over benchmark



-8.3% under benchmark




+158% over benchmark

Traditional vs. Specialty Trend Components

Traditional trend: 1.9%

Benchmark comparison: LABOR AND TRUST


- Traditional trend contributed 3.8% to the overall trend (38.6%)
- Traditional accounts for 57.7% of overall total plan paid and was down from 78.5% in the prior period



Specialty trend: 172.6%

Benchmark comparison: LABOR AND TRUST

- Specialty trend contributed 96.2% to the overall trend (38.6%)
- Specialty accounts for 42.3% of overall total plan paid and was up from 21.5% in the prior period



Top Disease States & Top 20 Drugs

Top Disease States

Top 5 disease states account for 77% of total Plan Paid

- Inflammatory Conditions accounts for 29.6% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug
- Diabetes accounts for 25.6% of total plan paid, with trend driven by Drug Mix. TRULICITY was the top drug

Sort by: Plan Paid

Inflammatory Conditions ▲

PMPM
\$46.49

Trend
100.6%

Top driver:
Utilization

Diabetes ▲

PMPM
\$40.29

Trend
40.9%

Top driver:
Drug Mix

Oncology ▲

PMPM
\$17.88

Trend
3,297.9%

Top driver:
Drug Mix

Cardiovascular ▲

PMPM
\$8.41

Trend
7.4%

Top driver:
Utilization

Asthma / COPD ▼

PMPM
\$7.35

Trend
-53.7%

Top driver:
Utilization

All other ▼

PMPM
\$36.91

Trend
-1.5%

Top 20 Drugs by Plan Cost

Specialty

All meds are Brands except indicated with a "G" for generic

Rank													Trend components	
Cu	Pv	Bench	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Top Trend	% Top driver
1	-	30	IBRANCE	Oncology	1	2	28.0	\$31,090	\$15,545.22	\$17.46	\$0.00	\$0.75	- -	-
2	1	6	DUPIXENT	Chronic Inflammatory Disease	3	9	28.0	\$24,661	\$2,740.06	\$13.85	\$10.87	\$2.64	27.3% Utilzn	59.1%
3	2	1	HUMIRA PEN	Chronic Inflammatory Disease	1	3	28.0	\$21,387	\$7,129.14	\$12.01	\$10.22	\$8.44	17.5% Cost	8.9%
4	-	7	SKYRIZI PEN	Chronic Inflammatory Disease	1	1	28.0	\$20,351	\$20,351.12	\$11.43	\$0.00	\$2.49	- -	-
5	7	5	TRULICITY	GLP-1 Receptor Agonists	4	12	28.3	\$10,062	\$838.47	\$5.65	\$3.29	\$3.17	71.9% Utilzn	61.0%
6	8	4	JARDIANCE	SGLT-2 Inhibitors & Combos	6	16	33.8	\$9,722	\$607.60	\$5.46	\$3.28	\$3.32	66.5% Utilzn	59.1%
7	11	18	OTEZLA	Chronic Inflammatory Disease	1	2	30.0	\$9,465	\$4,732.70	\$5.31	\$2.09	\$1.10	154.8% Cost	154.8%
8	-	10	TALTZ	Chronic Inflammatory Disease	1	1	28.0	\$6,940	\$6,940.24	\$3.90	\$0.00	\$1.77	- -	-
9	6	43	VICTOZA	GLP-1 Receptor Agonists	2	4	45.0	\$6,348	\$1,587.04	\$3.56	\$3.29	\$0.49	8.3% Utilzn	6.1%
10	20	2	OZEMPIC	GLP-1 Receptor Agonists	3	3	66.0	\$5,970	\$1,989.99	\$3.35	\$1.28	\$4.65	162.8% Utilzn	150.0%
11	10	26	JANUMET	DPP-4 Inhibitors & Combos	3	8	30.0	\$4,183	\$522.93	\$2.35	\$2.31	\$0.86	1.5% Utilzn	-5.7%
12	5	203	STRIBILD	HIV-Multiclass Combo	1	1	30.0	\$3,879	\$3,878.76	\$2.18	\$4.00	\$0.09	-45.5% Utilzn	-47.0%
13	13	27	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	4	45.0	\$3,768	\$941.93	\$2.12	\$1.91	\$0.86	10.8% Cost	6.7%
14	14	12	JANUVIA	DPP-4 Inhibitors & Combos	3	7	30.0	\$3,570	\$509.93	\$2.00	\$1.85	\$1.72	8.2% Utilzn	6.1%
15	23	130	BYDUREON BCISE	GLP-1 Receptor Agonists	1	4	29.0	\$3,097	\$774.37	\$1.74	\$1.20	\$0.16	45.0% Utilzn	43.1%
16	-	11	MOUNJARO	GLP-1 Receptor Agonists	2	3	28.0	\$2,970	\$990.02	\$1.67	\$0.00	\$1.73	- -	-
17	34	367	MYCOPHENOLATE MOFETIL	Transplant	1	2	90.0	\$2,943	\$1,471.57	\$1.65	\$0.78	\$0.04	112.1% Utilzn	112.1%
18	4	9	BIKTARVY	HIV-Multiclass Combo	1	1	30.0	\$2,795	\$2,794.66	\$1.57	\$4.80	\$2.15	-67.3% Utilzn	-64.6%
19	16	15	LANTUS SOLOSTAR	Insulin	8	8	37.5	\$2,691	\$336.35	\$1.51	\$1.64	\$1.39	-7.9% Cost	-35.2%
20	-	23	WEGOVY	Anti-Obesity Agents	1	2	28.0	\$2,620	\$1,309.99	\$1.47	\$0.00	\$0.99	- -	-
Total					35	93	34.3	\$178,512	\$1,919.49	\$100.23	\$52.81	\$38.80	89.8%	45.6%
Plan Total					305	1,735	30.9	\$280,188	\$161.49	\$157.32	\$113.49	\$119.55	38.6%	36.7%

Rebates


Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Mar 2023

Benchmark: LABOR AND TRUST

Current rebate value: \$24.99 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$132.33, versus plan paid PMPM of \$157.32.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$101.64	\$10.97	\$90.70	\$16.35	\$74.35
Specialty	\$71.62	\$4.99	\$66.62	\$8.64	\$57.98
Total	\$173.25	\$15.96	\$157.32	\$24.99	\$132.33

Total estimated rebate yield for reporting period: **\$44.5K**

Rebate Performance by Disease State

Disease ↕	Drug cost PMPM ↕	Member paid PMPM ↕	Plan paid PMPM ↕	Rebates PMPM ↕	Net plan paid PMPM ↕	Rebate offset ↕
Diabetes	\$43.00	\$2.72	\$40.29	\$9.03	\$31.26	22.4%
Inflammatory Conditions	\$51.42	\$4.92	\$46.49	\$7.68	\$38.81	16.5%
Asthma / COPD	\$7.75	\$0.40	\$7.35	\$2.43	\$4.92	33.0%
Cardiovascular	\$10.43	\$2.03	\$8.41	\$1.26	\$7.15	15.0%
Oncology	\$17.93	\$0.06	\$17.88	\$0.96	\$16.92	5.4%
Blood Clot Prevention/Stroke Prevention	\$2.47	\$0.15	\$2.32	\$0.67	\$1.65	29.1%
Diabetic Supplies	\$1.41	\$0.16	\$1.25	\$0.58	\$0.67	46.7%
Gastrointestinal, Misc	\$1.33	\$0.07	\$1.26	\$0.45	\$0.81	35.7%
Male And Female Hormone Replacement	\$1.24	\$0.09	\$1.15	\$0.27	\$0.88	23.5%
Cholesterol Lowering Agents	\$4.22	\$1.11	\$3.10	\$0.22	\$2.88	7.2%
Overactive Bladder / Incontinence	\$0.91	\$0.04	\$0.87	\$0.18	\$0.69	20.7%
Glaucoma	\$1.09	\$0.10	\$1.00	\$0.18	\$0.82	18.0%
Kidney Disease	\$1.13	\$0.03	\$1.09	\$0.18	\$0.91	16.4%
Contraception	\$1.48	\$0.03	\$1.45	\$0.18	\$1.27	12.4%
Weight Loss	\$1.49	\$0.02	\$1.47	\$0.18	\$1.29	12.2%
HIV	\$5.23	\$0.58	\$4.66	\$0.18	\$4.48	3.9%
Migraine/Pain Relief	\$0.54	\$0.08	\$0.46	\$0.09	\$0.37	19.5%
Antipsychotics	\$0.99	\$0.05	\$0.94	\$0.09	\$0.85	9.6%
Antibiotics	\$2.24	\$0.31	\$1.93	\$0.09	\$1.84	4.7%
Misc Skin Condition	\$2.47	\$0.26	\$2.21	\$0.09	\$2.12	4.1%

Clinical Outcomes


UM Outcomes

Utilization management savings: \$12.73 PMPM

Your program savings: **\$93.1K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$93.1K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.

Prior auth Quantity limits Step therapy



Outcomes date range: Jul 2021 - Jun 2022

Prior authorization

PMPM SAVINGS

\$6.61

NUMBER OF MEMBERS IMPACTED

43

NUMBER OF INTERVENTIONS

55

Quantity limits

PMPM SAVINGS

\$2.81

NUMBER OF MEMBERS IMPACTED

5

NUMBER OF INTERVENTIONS

6

Step therapy

PMPM SAVINGS

\$3.31

NUMBER OF MEMBERS IMPACTED

83

NUMBER OF INTERVENTIONS

92

QL savings is based only on Maximum Daily Dose edits.

Vigilant Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Apr 2022 - Mar 2023

Total program savings: \$0.78 PMPM

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$5.7K in pharmacy spend
- Switched 8 claims to lower cost alternatives
- 9 claims were abandoned



TOTAL PLAN PAID SAVINGS

\$5,726

TOTAL PROGRAM SAVINGS

0.5%

TOTAL MEMBERS IMPACTED

17

Savings by Vigilant Drug List

Sort by: Members impacted

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	\$0.40	9	9
Clinical Duplicates	\$0.12	3	3
High Cost Brands with Generics	\$0.00	2	2
Creams & Patches	\$0.03	1	1
New Drugs to Market	\$0.17	1	1
Non-FDA Approved Drugs	\$0.06	1	1

VCS (variable copay solutions) Outcomes

Total program savings: \$4.86 PMPM

Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- \$8,664 in Plan Paid savings
- \$1,083.00 average Plan Paid per impacted prescription
- 3 total impacted utilizers

PLAN PAID SAVINGS

\$8,664

PLAN PAID SAVINGS PER IMPACTED RX

\$1,083.00

Top 5 drugs based on: Plan paid savings

DUPIXENT

IMPACTED RXS

8

IMPACTED UTILIZERS


3

PLAN PAID SAVINGS

\$8,664


Drug Pipeline

Selected Generic Launches in 2023 and early 2024



[†] Generic has 180-days of exclusivity
ADHD = Attention deficit hyperactivity disorder
COPD = Chronic obstructive pulmonary disease

Select Pipeline Drugs expected 2Q 2023 to 4Q 2023




Appendix

Trend Components

Total trend: 38.6%

Benchmark comparison: LABOR AND TRUST

- Bakers Union and FELRA Health and Welfare Fund's overall trend of 38.6% was 26.5% higher than benchmark
- Specialty spend influenced the trend contributing 96.2% (41.8% higher than benchmark)
- Traditional trend contributed 3.8% (41.8% lower than benchmark)



Top 20 traditional

All meds are Brands

Rank														Trend components		
Cu	Pv	Bench	Drug name		Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	5	3	TRULICITY	★	GLP-1 Receptor Agonists	4	12	28.3	\$10,062	\$838.47	\$5.65	\$3.29	\$3.17	71.9%	Utilzn	61.0%
2	6	2	JARDIANCE	★	SGLT-2 Inhibitors & Combos	6	16	33.8	\$9,722	\$607.60	\$5.46	\$3.28	\$3.32	66.5%	Utilzn	59.1%
3	4	22	VICTOZA	★	GLP-1 Receptor Agonists	2	4	45.0	\$6,348	\$1,587.04	\$3.56	\$3.29	\$0.49	8.3%	Utilzn	6.1%
4	17	1	OZEMPIC	★	GLP-1 Receptor Agonists	3	3	66.0	\$5,970	\$1,989.99	\$3.35	\$1.28	\$4.65	162.8%	Utilzn	150.0%
5	8	15	JANUMET	★	DPP-4 Inhibitors & Combos	3	8	30.0	\$4,183	\$522.93	\$2.35	\$2.31	\$0.86	1.5%	Utilzn	-5.7%
6	3	105	STRIBILD		HIV-Multiclass Combo	1	1	30.0	\$3,879	\$3,878.76	\$2.18	\$4.00	\$0.09	-45.5%	Utilzn	-47.0%
7	10	16	ENTRESTO		Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	4	45.0	\$3,768	\$941.93	\$2.12	\$1.91	\$0.86	10.8%	Cost	6.7%
8	11	7	JANUVIA	★	DPP-4 Inhibitors & Combos	3	7	30.0	\$3,570	\$509.93	\$2.00	\$1.85	\$1.72	8.2%	Utilzn	6.1%
9	20	71	BYDUREON BCISE	★	GLP-1 Receptor Agonists	1	4	29.0	\$3,097	\$774.37	\$1.74	\$1.20	\$0.16	45.0%	Utilzn	43.1%
10	-	6	MOUNJARO	★	GLP-1 Receptor Agonists	2	3	28.0	\$2,970	\$990.02	\$1.67	\$0.00	\$1.73	-	-	-
11	2	5	BIKTARVY		HIV-Multiclass Combo	1	1	30.0	\$2,795	\$2,794.66	\$1.57	\$4.80	\$2.15	-67.3%	Utilzn	-64.6%
12	13	9	LANTUS SOLOSTAR	★	Insulin	8	8	37.5	\$2,691	\$336.35	\$1.51	\$1.64	\$1.39	-7.9%	Cost	-35.2%
13	-	12	WEGOVY		Anti-Obesity Agents	1	2	28.0	\$2,620	\$1,309.99	\$1.47	\$0.00	\$0.99	-	-	-
14	-	11	HUMALOG KWIKPEN	★	Insulin	4	6	24.5	\$2,600	\$433.30	\$1.46	\$0.00	\$1.05	-	-	-
15	16	4	ELIQUIS		Oral Anticoagulants	2	5	30.0	\$2,546	\$509.16	\$1.43	\$1.28	\$2.28	11.9%	Utilzn	7.5%
16	29	107	SOLIQUA 100/ 33	★	Insulin	1	1	90.0	\$2,484	\$2,484.32	\$1.39	\$0.83	\$0.08	68.3%	Utilzn	59.1%
17	18	675	HUMALOG MIX 50/ 50 KWIKPEN	★	Insulin	1	1	90.0	\$2,449	\$2,449.09	\$1.38	\$1.26	\$0.01	8.8%	Utilzn	6.1%
18	12	87	LANTUS	★	Insulin	2	5	25.6	\$2,425	\$484.97	\$1.36	\$1.75	\$0.12	-22.0%	Cost	-53.3%
19	1	19	SYMBICORT		Inhaled Asthma/COPD Combo	3	6	21.7	\$2,167	\$361.09	\$1.22	\$5.56	\$0.66	-78.1%	Utilzn	-86.1%
20	-	39	XIFAXAN		Anti-Infective Agents - Misc.	1	1	14.0	\$2,157	\$2,156.95	\$1.21	\$0.00	\$0.31	-	-	-
Total						37	98	33.2	\$78,501	\$801.03	\$44.08	\$39.53	\$26.08	11.5%		8.8%
Plan Total						304	1,711	30.7	\$161,529	\$94.41	\$90.70	\$89.04	\$64.06	1.9%		6.3%

Top 20 specialty

B = Brands
G = Generics

Rank			Trend components												
Cu	Pv	Bench	Drug name		Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Top Trend	% Top driver
1	-	13	IBRANCE	B	Oncology	1	2	28.0	\$31,090	\$15,545.22	\$17.46	\$0.00	\$0.75	- -	-
2	1	3	DUPIXENT	B	Chronic Inflammatory Disease	3	9	28.0	\$24,661	\$2,740.06	\$13.85	\$10.87	\$2.64	27.3% Utilzn	59.1%
3	2	1	HUMIRA PEN	B	Chronic Inflammatory Disease	1	3	28.0	\$21,387	\$7,129.14	\$12.01	\$10.22	\$8.44	17.5% Cost	8.9%
4	-	4	SKYRIZI PEN	B	Chronic Inflammatory Disease	1	1	28.0	\$20,351	\$20,351.12	\$11.43	\$0.00	\$2.49	- -	-
5	3	8	OTEZLA	B	Chronic Inflammatory Disease	1	2	30.0	\$9,465	\$4,732.70	\$5.31	\$2.09	\$1.10	154.8% Cost	154.8%
6	-	5	TALTZ	B	Chronic Inflammatory Disease	1	1	28.0	\$6,940	\$6,940.24	\$3.90	\$0.00	\$1.77	- -	-
7	4	183	MYCOPHENOLATE MOFETIL	G	Transplant	1	2	90.0	\$2,943	\$1,471.57	\$1.65	\$0.78	\$0.04	112.1% Utilzn	112.1%
8	5	168	TACROLIMUS	G	Transplant	1	4	90.0	\$1,821	\$455.19	\$1.02	\$0.48	\$0.04	112.1% Utilzn	112.1%
Total						7	24	43.7	\$118,659	\$4,944.13	\$66.62	\$24.44	\$18.01	172.6%	112.9%
Plan Total						7	24	43.7	\$118,659	\$4,944.13	\$66.62	\$24.44	\$55.48	172.6%	112.9%

5 out of the top 8 are for Chronic Inflammatory Disease

3 out of the top 8 have moved up in rank